German psychedelic startup Atai targets valuation of $2.3 bln in U.S. IPO
June 11 (Reuters) - ATAI Life Sciences B.V., backed by billionaire investor Peter Thiel, said on Friday it is looking to raise as much as $214.3 million through a U.S. initial public offering, targeting a valuation of about $2.3 billion.
The Berlin-based biotech startup, which is exploring the use of psychedelic treatments for mental health disorders, said it plans to sell around 14.29 million shares priced between $13 and $15 per share. (https://bit.ly/3iA5ste) (Reporting by Sohini Podder in Bengaluru; Editing by Amy Caren Daniel)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.